X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ADXN

Closed

Addex Therapeutics Ltd

9.2
-0.2 (-2.13%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 9.41
Day's Range: 8.99 - 9.87
Send
When Written:
 
0.93
Addex Therapeutics Ltd is a clinical-stage pharmaceutical company based in Geneva, Switzerland. The company focuses on developing novel small molecule drugs to treat neurological disorders such as Parkinson's disease, epilepsy, and addiction.

Addex's lead product candidate is dipraglurant, a selective metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). The company is also developing other mGluR5 NAMs for the treatment of other neurological disorders.

In addition to its mGluR5 program, Addex is developing drugs that target other receptor families, including GABA-B receptors and adenosine receptors, for the treatment of various neurological disorders.

Addex was founded in 2002 and is publicly traded on the SIX Swiss Exchange under the symbol ADXN. The company has collaborations with several pharmaceutical companies, including Janssen Pharmaceuticals, Merck & Co., and Indivior.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.209
X